NEW YORK, June 12, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Summit Therapeutics Inc. ("Summit" or the "Company") (NASDAQ: SMMT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980. The investigation concerns whether Summit and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining the class action] On this news, Summ ...

An analyst's downbeat new take on Summit Therapeutics (SMMT -11.32%) pushed its stock downward on Hump Day. At the end of Wednesday, the shares had booked a loss of over 11% in price as investors absorbed the negative take. That was a far steeper fall than the 0.3% slide of the S&P 500 (^GSPC -0.27%) that trading session.Bearish on SummitWell before market open that day, Leerink Partners' Daina Graybosch initiated coverage on Summit stock. This wasn't a positive appraisal, as the analyst flagged it with an ...

NEW YORK, June 10, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Summit Therapeutics Inc. (“Summit” or the “Company”) (NASDAQ: SMMT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Summit and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.  [Click here for information about joining the class action] On May 30, ...

9 June 2025 | 5:15PM EDT Goldman Sachs does and seeks to do business with companies covered in its research reports. As a result, investors should be aware that the firm may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only a single factor in making their investment decision. For Reg AC certification and other important disclosures, see the Disclosure Appendix, or go to www.gs.com/research/hedge.html. Analysts employed by non-US affil ...

Summit Therapeutics (SMMT) FY 2025 Conference June 09, 2025 01:20 PM ET Speaker0 Great. Good afternoon, everyone. Thank you so much for joining us. I'm Salveen Richter, Biotechnology Analyst at Goldman Sachs. And we're really pleased to be joined by the Summit team who's rather patriotic today. So to start here next to me, have Mickey Zengene, who's Co CEO Bob Duggan, Co CEO Manmeet, Sony, COO and CFO and Dave Genzar's Chief Business Officer. So with that, to start here, could you provide an overview of you ...

NEW YORK, June 06, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of  Summit Therapeutics Inc. (“Summit” or the “Company”) (NASDAQ: SMMT).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Summit and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.  [Click here for information about joining the class action] On May 3 ...

A downtrend has been apparent in Summit Therapeutics PLC (SMMT) lately with too much selling pressure. The stock has declined 36.7% over the past four weeks. However, given the fact that it is now in oversold territory and Wall Street analysts are majorly in agreement about the company's ability to report better earnings than they predicted earlier, the stock could be due for a turnaround.How to Determine if a Stock is OversoldWe use Relative Strength Index (RSI), one of the most commonly used technical ind ...

Group 1 - Elle Investments is a small family office focused on identifying asymmetric investment opportunities created by a disconnect between value and market sentiment [1] - The firm employs a "quantamental approach" to manage long-term portfolio risk, aiming to deliver alpha over the long term [1] Group 2 - The article does not provide specific financial data or performance metrics related to the investments or the market [2][3]

POLAND - 2025/01/09: In this photo illustration, the Summit Therapeutics company logo is seen ... More displayed on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)SOPA Images/LightRocket via Getty ImagesSummit Therapeutics (NASDAQ: SMMT) experienced a significant 30% decrease in its stock on Friday, May 30th, closing at $18. This sudden decline came even though the stock had doubled within the past year, driven by favorable updates regarding its lung cancer m ...

Core Viewpoint - Summit Therapeutics' stock experienced a significant decline of over 30% due to disappointing results from the Harmoni trial of ivonescimab, a bispecific antibody aimed at treating lung cancer [1][2]. Group 1: Clinical Trial Results - The Harmoni trial aimed to evaluate ivonescimab in second-line lung cancer patients, showing a 48% reduction in disease progression risk but failing to demonstrate a statistically significant overall survival benefit [6]. - The treatment reduced the risk of death by 21%, but the results were just outside the 95% confidence interval with a p-value of 0.057, indicating a lack of convincing evidence for overall survival [6][7]. - The FDA is unlikely to approve ivonescimab in the U.S. based on these trial results, as a statistically significant overall survival benefit is required for approval [7]. Group 2: Market Context and Comparisons - Keytruda, a leading treatment for lung cancer, generated $29.5 billion in sales last year, setting a high benchmark for any competing therapies like ivonescimab [9]. - Despite the lack of overall survival data, ivonescimab's ability to shrink tumors suggests potential for future success in different patient populations [9][11]. - The stock of Summit Therapeutics finished May with a market cap exceeding $13.5 billion, despite having no sales and only one candidate in its pipeline [12]. Group 3: Investment Considerations - The lack of convincing overall survival data for ivonescimab diminishes the likelihood of it achieving blockbuster sales, even if it eventually receives FDA approval [11][13]. - Investors may face challenges ahead, as expectations remain high despite the uncertain path for ivonescimab [11].